{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T18:11:42Z","timestamp":1770833502217,"version":"3.50.1"},"reference-count":39,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","license":[{"start":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T00:00:00Z","timestamp":1750809600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>C-reactive protein (CRP) has long been identified as a potential therapeutic target to improve outcomes in acute myocardial infarction (AMI). Recently, CRP apheresis has shown promising results from first-in-human case reports, registries, and pilot trials in patients with COVID-19, acute ST-segment elevation myocardial infarction, cardiogenic shock, and non-ST-segment elevation acute coronary syndromes.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods and Results<\/jats:title>\n            <jats:p>Herein we describe the perspective for a pivotal, international, randomized controlled trial investigating CRP apheresis in AMI. We herein propose the rationale, design, endpoints, and statistical methodology of this study.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>The goal is to demonstrate the safety and efficacy of CRP apheresis in AMI in reducing the combined primary clinical endpoint of cardiovascular mortality or rehospitalization for heart failure.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/mca.0000000000001521","type":"journal-article","created":{"date-parts":[[2025,3,30]],"date-time":"2025-03-30T01:11:48Z","timestamp":1743297108000},"page":"428-433","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Selective C-reactive protein apheresis in acute myocardial infarction: rationale and design of a prospective international randomized controlled trial"],"prefix":"10.1097","volume":"36","author":[{"given":"Jan","family":"Torzewski","sequence":"first","affiliation":[{"name":"Cardiovascular Center Oberallgaeu-Kempten, Clinic Association Allgaeu, Kempten"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephan","family":"Mattecka","sequence":"additional","affiliation":[{"name":"Capture Biotech GmbH, Berlin"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin","family":"Mayer","sequence":"additional","affiliation":[{"name":"Institute of Epidemiology and Medical Biometry, University of Ulm, Ulm, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregg W.","family":"Stone","sequence":"additional","affiliation":[{"name":"Icahn School of Medicine at Mount Sinai, New York City, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed","family":"Sheriff","sequence":"additional","affiliation":[{"name":"Capture Biotech GmbH, Berlin"},{"name":"Department of Gastroenterology\/Infectiology\/Rheumatology, Charite\u0301 University Medicine Berlin, Berlin, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2025,6,25]]},"reference":[{"key":"R1-20250626","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1159\/000320763","article-title":"Specific removal of C-reactive protein by apheresis in a porcine cardiac infarction model.","volume":"31","author":"Slagman","year":"2011","journal-title":"Blood Purif"},{"key":"R2-20250626","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/jca.21344","article-title":"Selective apheresis of C-reactive protein: a new therapeutic option in myocardial infarction?","volume":"30","author":"Sheriff","year":"2014","journal-title":"J Clin Apher"},{"key":"R3-20250626","first-page":"4767105","article-title":"First in man\u2019: case report of selective C-reactive protein apheresis in a patient with acute ST segment elevation myocardial infarction.","volume":"2018","author":"Ries","year":"2018","journal-title":"Case Rep Cardiol"},{"key":"R4-20250626","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1111\/1744-9987.12804","article-title":"Selective C-reactive protein-apheresis in patients.","volume":"23","author":"Ries","year":"2019","journal-title":"Ther Apher Dial"},{"key":"R5-20250626","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1159\/000510554","article-title":"Early selective C-reactive protein apheresis in a patient with acute ST segment elevation myocardial reinfarction.","volume":"50","author":"Milosevic","year":"2021","journal-title":"Blood Purif"},{"key":"R6-20250626","doi-asserted-by":"crossref","first-page":"e925020","DOI":"10.12659\/AJCR.925020","article-title":"First-in-man: case report of selective C-reactive protein apheresis in a patient with SARS-cov-2 infection.","volume":"21","author":"Torzewski","year":"2020","journal-title":"Am J Case Rep"},{"key":"R7-20250626","doi-asserted-by":"crossref","first-page":"e932964","DOI":"10.12659\/AJCR.932964","article-title":"Successful treatment of a 39-year-old COVID-19 patient with respiratory failure by selective C-reactive protein apheresis.","volume":"22","author":"Torzewski","year":"2021","journal-title":"Am J Case Rep"},{"key":"R8-20250626","doi-asserted-by":"crossref","first-page":"708101","DOI":"10.3389\/fimmu.2021.708101","article-title":"Case report: C-reactive protein apheresis in a patient with COVID-19 and fulminant CRP increase.","volume":"12","author":"Ringel","year":"2021","journal-title":"Front Immunol"},{"key":"R9-20250626","doi-asserted-by":"crossref","first-page":"e935263","DOI":"10.12659\/AJCR.935263","article-title":"A report on the first 7 sequential patients treated within the C-Reactive Protein Apheresis in COVID (CACOV) Registry.","volume":"23","author":"Schumann","year":"2021","journal-title":"Am J Case Rep"},{"key":"R10-20250626","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.3390\/jcm11071956","article-title":"Seven COVID-19 patients treated with C-reactive protein (CRP) apheresis.","volume":"11","author":"Esposito","year":"2022","journal-title":"J Clin Med"},{"key":"R11-20250626","doi-asserted-by":"crossref","first-page":"1286710","DOI":"10.3389\/fddsv.2023.1286710","article-title":"Case report: C-reactive protein apheresis in cardiogenic shock: case series from the C-reactive protein apheresis in acute myocardial infarction-registry.","volume":"3","author":"Torzewski","year":"2023","journal-title":"Front Drug Discov"},{"key":"R12-20250626","doi-asserted-by":"crossref","first-page":"1401566","DOI":"10.3389\/fcvm.2024.1401566","article-title":"Case report: C-reactive protein apheresis in non-ST-elevation ACS-case series from the C-reactive protein apheresis in Acute Myocardial Infarction Registry.","volume":"11","author":"Torzewski","year":"2024","journal-title":"Front Cardiovasc Med"},{"key":"R13-20250626","doi-asserted-by":"crossref","first-page":"591714","DOI":"10.3389\/fcvm.2021.591714","article-title":"C-reactive protein apheresis as anti-inflammatory therapy in acute myocardial infarction: results of the CAMI-1 study.","volume":"8","author":"Ries","year":"2021","journal-title":"Front Cardiovasc Med"},{"key":"R14-20250626","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1177\/2048872616661691","article-title":"Relation of inflammatory markers with myocardial and microvascular injury in patients with reperfused ST-elevation myocardial infarction.","volume":"6","author":"Reindl","year":"2017","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"key":"R15-20250626","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.5114\/aoms.2017.69327","article-title":"C-reactive protein levels predict systolic heart failure and outcome in patients with first ST-elevation myocardial infarction treated with coronary angioplasty.","volume":"13","author":"Stumpf","year":"2017","journal-title":"Arch Med Sci"},{"key":"R16-20250626","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.3390\/biomedicines11082279","article-title":"Being eaten alive: how energy-deprived cells are disposed of, mediated by C-reactive protein-including a treatment option.","volume":"11","author":"Sheriff","year":"2023","journal-title":"Biomedicines"},{"key":"R17-20250626","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1084\/jem.190.4.585","article-title":"The major receptor for C-reactive protein on leukocytes is fcgamma receptor II.","volume":"190","author":"Bharadwaj","year":"1999","journal-title":"J Exp Med"},{"key":"R18-20250626","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1161\/01.ATV.0000147407.17137.02","article-title":"Ultrasensitive confocal fluorescence microscopy of C-reactive protein interacting with FcgammaRIIa.","volume":"24","author":"Manolov","year":"2004","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R19-20250626","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.4049\/jimmunol.112.6.2135","article-title":"Interaction of C-reactive protein complexes with the complement system. I. Consumption of human complement associated with the reaction of C-reactive protein with pneumococcal C-polysaccharide and with the choline phosphatides, lecithin and sphingomyelin.","volume":"112","author":"Kaplan","year":"1974","journal-title":"J Immunol"},{"key":"R20-20250626","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1161\/01.CIR.95.1.97","article-title":"C-reactive protein colocalizes with complement in human hearts during acute myocardial infarction.","volume":"95","author":"Lagrand","year":"1997","journal-title":"Circulation"},{"key":"R21-20250626","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S0002-9440(10)64201-0","article-title":"Complement and dilated cardiomyopathy: a role of sublytic terminal complement complex-induced tumor necrosis factor-alpha synthesis in cardiac myocytes.","volume":"161","author":"Zwaka","year":"2002","journal-title":"Am J Pathol"},{"key":"R22-20250626","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.3390\/jcm11071771","article-title":"Targeting C-reactive protein by selective apheresis in humans: pros and cons.","volume":"11","author":"Torzewski","year":"2022","journal-title":"J Clin Med"},{"key":"R23-20250626","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S0140-6736(12)62160-6","article-title":"SPIRIT: new guidance for content of clinical trial protocols.","volume":"381","author":"Chan","year":"2013","journal-title":"Lancet"},{"key":"R24-20250626","doi-asserted-by":"crossref","first-page":"555","DOI":"10.2174\/1381612829666230310090601","article-title":"C-reactive protein apheresis in acute myocardial infarction.","volume":"29","author":"Milosevic","year":"2023","journal-title":"Curr Pharm Des"},{"key":"R25-20250626","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1016\/j.jacc.2021.12.011","article-title":"2022 AHA\/ACC\/HFSA Guideline for the Management of Heart Failure: Executive Summary: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines.","volume":"79","author":"Heidenreich","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"R26-20250626","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1093\/ehjacc\/zuad107","article-title":"2023 ESC guidelines for the management of acute coronary syndromes: developed by the task force on the management of acute coronary syndromes of the European Society of Cardiology (ESC).","volume":"13.1","author":"Byrne","year":"2024","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"key":"R27-20250626","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1016\/j.jacc.2016.01.069","article-title":"Relationship between infarct size and outcomes following primary PCI: patient-level analysis from 10 randomized trials.","volume":"67","author":"Stone","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"R28-20250626","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1002\/ccd.28329","article-title":"SCAI clinical expert consensus statement on the classification of cardiogenic shock: this document was endorsed by the American College of Cardiology (ACC), the American Heart Association (AHA), the Society of Critical Care Medicine (SCCM), and the Society of Thoracic Surgeons (STS) in April 2019.","volume":"94","author":"Baran","year":"2019","journal-title":"Catheter Cardiovasc Interv"},{"key":"R29-20250626","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.mayocp.2022.12.007","article-title":"Cardiogenic shock classification and associated mortality risk.","volume":"98","author":"Hill","year":"2023","journal-title":"Mayo Clin Proc"},{"key":"R30-20250626","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1001\/jama.2021.18323","article-title":"Cardiogenic shock after acute myocardial infarction: a review.","volume":"326","author":"Samsky","year":"2021","journal-title":"JAMA"},{"key":"R31-20250626","doi-asserted-by":"crossref","first-page":"965","DOI":"10.3390\/jcm12030965","article-title":"C-reactive protein and white blood cell count in cardiogenic shock.","volume":"12","author":"Dudda","year":"2023","journal-title":"J Clin Med"},{"key":"R32-20250626","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1093\/eurheartj\/ehr352","article-title":"The win ratio: a new approach to the analysis of composite endpoints in clinical trials based on clinical priorities.","volume":"33","author":"Pocock","year":"2012","journal-title":"Eur Heart J"},{"key":"R33-20250626","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.jchf.2020.02.010","article-title":"Use of the win ratio in cardiovascular trials.","volume":"8","author":"Ferreira","year":"2020","journal-title":"JACC Heart Fail"},{"key":"R34-20250626","doi-asserted-by":"crossref","first-page":"4391","DOI":"10.1093\/eurheartj\/ehaa665","article-title":"The win ratio approach for composite endpoints: practical guidance based on previous experience.","volume":"41","author":"Redfors","year":"2020","journal-title":"Eur Heart J"},{"key":"R35-20250626","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1002\/sim.9297","article-title":"Sample size formula for a win ratio endpoint.","volume":"41","author":"Yu","year":"2022","journal-title":"Stat Med"},{"key":"R36-20250626","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/ncpneph0778","article-title":"C-reactive protein is neither a marker nor a mediator of atherosclerosis.","volume":"4","author":"Pepys","year":"2008","journal-title":"Nat Clin Pract Nephrol"},{"key":"R37-20250626","first-page":"646817","article-title":"C-reactive protein and arteriosclerosis.","volume":"2014","author":"Torzewski","year":"2014","journal-title":"Mediators Inflamm"},{"key":"R38-20250626","doi-asserted-by":"crossref","first-page":"14188","DOI":"10.1038\/ncomms14188","article-title":"Transitional changes in the CRP structure lead to the exposure of proinflammatory binding sites.","volume":"8","author":"Braig","year":"2017","journal-title":"Nat Commun"},{"key":"R39-20250626","doi-asserted-by":"crossref","first-page":"e16236","DOI":"10.15252\/emmm.202216236","article-title":"A novel phosphocholine-mimetic inhibits a pro-inflammatory conformational change in C-reactive protein.","volume":"15","author":"Zeller","year":"2023","journal-title":"EMBO Mol Med"}],"container-title":["Coronary Artery Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MCA.0000000000001521","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T09:00:28Z","timestamp":1750928428000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MCA.0000000000001521"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,25]]},"references-count":39,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/mca.0000000000001521","relation":{},"ISSN":["0954-6928","1473-5830"],"issn-type":[{"value":"0954-6928","type":"print"},{"value":"1473-5830","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,25]]}}}